+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Obesity

  • ID: 4846137
  • Report
  • February 2020
  • Region: Global
  • 62 pages
  • Datamonitor Healthcare
1 of 3

Enquire about COVID-19 updates for this product.

Enquire Now

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Gubra
  • Novo Nordisk
  • MORE
This Market Spotlight report covers the Obesity market, comprising key marketed and pipeline drugs, clinical trials, recent events and analyst opinion, key upcoming and regulatory events, probability of success, patent information, a 10-year disease prevalence forecast, and licensing and acquisition deals, as well as presenting drug-specific revenue forecasts.

Key Takeaways

The research estimates that in 2017, there were approximately 681.3 million prevalent cases of obesity in adults (aged 20+ years) worldwide, and expects that number to increase to 762.9 million prevalent cases by 2026.

In the same year, The research estimates that there were 126.6 million prevalent cases of obesity in children and adolescents (aged 5–19 years) worldwide, and expects that number to increase to 134.0 million prevalent cases by 2026.

Prevalence proportions are highest in Northern America and lowest in Asia. The approved drugs in the obesity space target gastric lipase, dopamine, norepinephrine (noradrenaline), dopamine reuptake, norepinephrine (noradrenaline) reuptake/transporter, opioid receptors, GABA-A receptor, serotonin 5-HT2C receptor, and glucagon-like peptide-1 (GLP-1) receptor. The majority of marketed drugs are administered via the oral route, with one product being available in a subcutaneous formulation.

The majority of industry-sponsored drugs in active clinical development for obesity are in Phase I, with two drugs in Phase III. Therapies in development for obesity focus on a wide variety of targets, with the subcutaneous route being the most common method of delivery.

High-impact upcoming events for drugs in the obesity space comprise expected PDUFA dates for Qsymia, Belviq, and Belviq XR, topline Phase II trial results for AM833, topline Phase III trial results for Ozempic, and an expected decentralized EU approval as well as an estimated EU patent expiration for Qsymia.

The overall likelihood of approval of a Phase I obesity asset is 2.6%, and the average probability a drug advances from Phase III is 62.5%. Drugs, on average, take 8.5 years from Phase I to approval, compared to 8.9 years in the overall metabolic space.

There have been 34 licensing and asset acquisition deals involving obesity drugs during 2015–20. The largest deal was the $301.1m collaboration and license agreement signed in 2017 between Boehringer Ingelheim and Gubra for the development of novel peptide compounds to treat obesity.

The distribution of clinical trials across Phase I–IV indicates that the majority of trials for obesity have been in the early and midphases of development, with 66% of trials in Phase I–II, and 34% in Phase III–IV.

The US has a substantial lead in the number of obesity clinical trials globally. The UK leads the major European markets, while Japan has the top spot in Asia.

Clinical trial activity in the obesity space is dominated by completed trials. AstraZeneca has the highest number of completed clinical trials for obesity, with 76 trials.

Novo Nordisk leads industry sponsors with the highest overall number of clinical trials for obesity, followed by AstraZeneca.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • AstraZeneca
  • Boehringer Ingelheim
  • Gubra
  • Novo Nordisk
  • MORE
1. OVERVIEW

2. KEY TAKEAWAYS

3. DISEASE BACKGROUND

4. TREATMENT
  • Medications
  • Surgery
5. EPIDEMIOLOGY

6. MARKETED DRUGS

7. PIPELINE DRUGS

8. RECENT EVENTS AND ANALYST OPINION
  • HM12525A for Obesity (July 3, 2019)
  • NS-0200 for Obesity (June 8, 2019)
  • PLENITY for Obesity (April 14, 2019)
  • PLENITY for Obesity (March 25, 2019)
  • Qsymia for Obesity (January 15, 2019)
  • Lap-Band System for Obesity (December 17, 2018)
  • Obalon Balloon System for Obesity (November 15, 2018)
  • TransPyloric Shuttle for Obesity (November 14, 2018)
  • Obalon Balloon System for Obesity (November 13, 2018)
  • PLENITY for Obesity (November 13, 2018)
  • Belviq for Obesity (October 4, 2018)
  • Belviq for Obesity (August 26, 2018)
  • Belviq for Obesity (July 17, 2018)
9. KEY UPCOMING EVENTS

10. KEY REGULATORY EVENTS
  • Preparing For Qsymia Launch In Korea
  • BaroNova’s TransPyloric Shuttle Earns FDA Approval To Treat Obesity
  • Gelesis's Plenity Obesity Product Earns De Novo For Wide BMI Range
11. PROBABILITY OF SUCCESS

12. LICENSING AND ASSET ACQUISITION DEALS
  • Novo/Fauna Partnership Includes Options To Resulting Drug Candidates
  • Novo Nordisk Enters Its First Strategic RNAi Pact
  • Numaferm And Polpharma Sign Deals
  • BI Inks Second Obesity Pact With Denmark’s Gubra
  • Merck Extends Research Collaboration With NGM By Two Years
13. PARENT PATENTS

14. REVENUE OPPORTUNITY

15. CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
16. BIBLIOGRAPHY
  • Prescription information
17. APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of obesity in adults, 2017–26
Figure 2: Overview of pipeline drugs for obesity in the US
Figure 3: Pipeline drugs for obesity, by company
Figure 4: Pipeline drugs for obesity, by drug type
Figure 5: Pipeline drugs for obesity, by classification
Figure 6: NS-0200 for Obesity (June 8, 2019): Phase II - NS-WM-01
Figure 7: TransPyloric Shuttle for Obesity (November 14, 2018): ENDObesity II (US)
Figure 8: PLENITY for Obesity (November 13, 2018): Phase II - GLOW (EU & US)
Figure 9: Belviq for Obesity (October 4, 2018): Phase IV - CAMELLIA-TIMI 61 (CVOT Trial)
Figure 10: Belviq for Obesity (August 26, 2018): Phase IV - CAMELLIA-TIMI 61 (CVOT Trial)
Figure 11: Belviq for Obesity (July 17, 2018): Phase IV - CAMELLIA-TIMI 61 (CVOT Trial)
Figure 12: Key upcoming events in obesity
Figure 13: Probability of success in the obesity pipeline
Figure 14: Licensing and asset acquisition deals in obesity, 2015–20
Figure 15: Parent patents in obesity
Figure 16: Clinical trials in obesity
Figure 17: Top 10 drugs for clinical trials in obesity
Figure 18: Top 10 companies for clinical trials in obesity
Figure 19: Trial locations in obesity
Figure 20: Obesity trials status
Figure 21: Obesity trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of obesity in adults, 2017–26
Table 2: Prevalent cases of morbid obesity in adults, 2017–26
Table 3: Prevalent cases of obesity in children and adolescents, 2017–26
Table 4: Prevalence proportions of obesity and morbid obesity, 2017
Table 5: Marketed drugs for obesity
Table 6: Pipeline drugs for obesity in the US
Table 7: HM12525A for Obesity (July 3, 2019)
Table 8: NS-0200 for Obesity (June 8, 2019)
Table 9: PLENITY for Obesity (April 14, 2019)
Table 10: PLENITY for Obesity (March 25, 2019)
Table 11: Qsymia for Obesity (January 15, 2019)
Table 12: Lap-Band System for Obesity (December 17, 2018)
Table 13: Obalon Balloon System for Obesity (November 15, 2018)
Table 14: TransPyloric Shuttle for Obesity (November 14, 2018)
Table 15: Obalon Balloon System for Obesity (November 13, 2018)
Table 16: PLENITY for Obesity (November 13, 2018)
Table 17: Belviq for Obesity (October 4, 2018)
Table 18: Belviq for Obesity (August 26, 2018)
Table 19: Belviq for Obesity (July 17, 2018)
Table 20: Historical global sales, by drug ($m), 2014–18
Table 21: Forecasted global sales, by drug ($m), 2020–24
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • AstraZeneca
  • Boehringer Ingelheim
  • Gubra
  • Novo Nordisk
Note: Product cover images may vary from those shown
Adroll
adroll